Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, Ibrahim A, McKee AE, Pazdur R, Beaver JA. Suzman DL, et al. Among authors: agrawal s. Oncologist. 2019 Apr;24(4):563-569. doi: 10.1634/theoncologist.2018-0084. Epub 2018 Dec 12. Oncologist. 2019. PMID: 30541754 Free PMC article. Clinical Trial.
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Apolo AB, et al. Among authors: agrawal s. JAMA Oncol. 2019 Dec 1;5(12):1790-1798. doi: 10.1001/jamaoncol.2019.4114. JAMA Oncol. 2019. PMID: 31670753 Free PMC article.
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer.
Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, Choueiri TK, Uzzo R, Apolo AB. Agrawal S, et al. JAMA Oncol. 2020 Jan 1;6(1):133-141. doi: 10.1001/jamaoncol.2019.4117. JAMA Oncol. 2020. PMID: 31750870 Free PMC article.
Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies.
Brewer JR, Chang E, Agrawal S, Singh H, Suzman DL, Xu J, Weinstock C, Fernandes LL, Cheng J, Zhang L, Xie D, Goldberg KB, Bloomquist EW, Tang S, Sridhara R, Theoret MR, Pazdur R, Ibrahim A, Beaver JA. Brewer JR, et al. Among authors: agrawal s. Clin Cancer Res. 2020 Dec 15;26(24):6406-6411. doi: 10.1158/1078-0432.CCR-19-4229. Epub 2020 Jul 30. Clin Cancer Res. 2020. PMID: 32732222
FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Kluetz PG, Keegan P, Demetri GD, Thornton K, Sul J, Kim J, Katzen H, Burke LB, Harvey RD, Alebachew E, Agrawal S, Nair A, Donoghue M, Pierce WF, Shord SS, Gao JJ, Pazdur R. Kluetz PG, et al. Among authors: agrawal s. Clin Cancer Res. 2021 Feb 15;27(4):916-921. doi: 10.1158/1078-0432.CCR-20-3213. Epub 2020 Nov 30. Clin Cancer Res. 2021. PMID: 33257426
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V, Weinstock C, Suzman DL, Agrawal S, Chang E, Anscher MS, Chi DC, Xu JX, Brewer JR, Brave MH, Hadadi M, Theoret MR, Kluetz PG, Goldberg KB, Ibrahim A, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L, Singh H. Fallah J, et al. Among authors: agrawal s. Lancet Oncol. 2021 Sep;22(9):1230-1239. doi: 10.1016/S1470-2045(21)00334-X. Epub 2021 Jul 23. Lancet Oncol. 2021. PMID: 34310904
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. Fallah J, et al. Among authors: agrawal s. Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875. Clin Cancer Res. 2023. PMID: 36469000 Free PMC article. Clinical Trial.
4,306 results